Background Previous articles have reported that expression levels of microRNAs (miRNAs) are associated with survival time of patients with gastric cancer (GC). 106b, 125a, 137, 141, 145, 146a, 196a, 196b, 206, 214, 218, 451, 486-5p and 506 demonstrate significantly prognostic value. Among them, miR-20b, 125a, 137, 141, 146a, 196a, 206, 218, 486-5p and 506 are strong biomarkers of prognosis in GC. hybridization; OS: overall survival; RFS: recurrence-free survival; CSS: cause-specific survival; DFS: disease-free survival; PFS: progression-free survival; uUnivariate analysis; mMultivariate analysis. In order to facilitate read and statistics, studies estimating prognostic value of different miRNAs are shown in blue and white; studies which cannot be merged are shown in yellow. Meta-analysis A summary of the HR evaluated from the whole combined analysis for all the miRNAs was shown in Table ?Table33. Table 3 Summary of the HR for miRNA expression in gastric cancer thead th align=”left” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ miRNA /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ Survival analysis /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ Number of articles /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ Included references /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ HR /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ 95%CI /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ Physique /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ P value /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ Heterogeneity (Higgins I2 statistic) /th th align=”center” valign=”middle” style=”background-color:#5abae8″ rowspan=”1″ colspan=”1″ Total patients /th /thead High miR-20aOS33,5,111.250.84-1.8730.27I2=70.7%, P=0.03199High miR-20bOS33,12,132.381.16-4.8730.02I2=0.0%, P=0.60178High miR-21RFS/CSS36,14,172.100.72-6.122A0.17I2=65.6%, P=0.06180High miR-21OS53,15,16,18,191.771.01-3.082A 0.05I2=57.8%, P=0.05327Low miR-27bOS332-341.180.75-1.8530.47I2=36.1%, P=0.21319Low miR-34aOS53,38-411.250.59-2.652D0.56I2=68.4%, P=0.13457Low miR-34aOSm238,401.560.95-2.552D0.08I2=51.0%, P=0.15213High miR-106bOS23,451.841.15-2.9430.01I2=0.0%, P=0.67157High miR-107OS33,46,471.520.42-5.5730.52I2=88.8%, P 0.01248Low Rabbit Polyclonal to CDC25C (phospho-Ser198) miR-125aOS349-512.061.26-3.374 0.01I2=0.0%, P=0.42230Low miR-137OS262,643.211.68-6.134 0.01I2=6.0%, P=0.35168Low miR-141OS265,672.471.34-4.564 0.01I2=0.0%, P=0.66125High miR-143OS23,700.680.12-3.8140.66I2=48.8%, P=0.1681Low miR-145OS334,56,721.621.07-2.4640.02I2=36.9%, P=0.21608Low miR-146aOS374-762.601.63-4.135 0.01I2=14.1%, P=0.31213High miR-150OS312,77,791.630.77-3.4550.20I2=47.8%, P=0.15223High miR-150RFS/PFS277,791.961.25-3.055 0.01I2=0.0%, P=0.79158Low miR-183OS356,83,841.460.55-3.8350.45I2=90.2%, P 0.01478High miR-192OS348,79,871.710.60-4.8550.31I2=87.0%, P 0.01140High miR-196aOS488,90-922.661.94-3.636 0.01I2=0.0%, P=0.62286High miR-196bOS456,91-931.671.38-2.026 0.01I2=0.0%, P=0.62625Low miR-200cOS396,98,990.650.16-2.6460.54I2=93.6%, P 0.01276Low miR-200cPFS/DFS366,96,981.200.60-2.3860.61I2=83.1%, P 0.01241Low miR-206OS3104-1062.851.73-4.707 0.01I2=0.0%, P=0.37468High miR-214OS41,34,110,1111.841.27-2.677 0.01I2=23.0%, P=0.27403Low miR-218OS3114-1162.611.74-3.927 0.01I2=0.0%, P=0.77220Low miR-335OS241,1270.850.03-27.5070.93I2=94.9%, P 0.01124Low miR-451OS34,141,1431.731.19-2.528 0.01I2=14.7%, P=0.31332Low miR-451DFS/RFS2141,1420.460.01-31.0680.72I2=95.0%, P 0.0190Low miR-486-5pOS356,147,1482.451.65-3.658 0.01I2=40.0%, P=0.19529Low miR-506OS3154-1562.071.33-3.238 0.01I2=0.0%, P=0.65288 Open in a separate window HR: hazard ratios; CI: confidence intervals; OS: overall survival; RFS: recurrence-free survival; CSS: cause-specific survival; PFS: progression-free survival; DFS: disease-free survival; mMultivariate analysis. High expression of miR-21 predicts poor OS Five studies [3, 15, 16, 18, 19] analyzed associations between high expression of miR-21 and OS, indicating that GC patients with high miR-21 expression had a significantly shorter OS than those with low miR-21 expression (HR=1.77, 95%CI=1.01-3.08, P 0.05, Figure ?Physique2A2A). Open in another window Body 2 (A) Forest story from the analyses about high appearance of miR-21 SKI-606 pontent inhibitor and RFS/CSS or Operating-system; (B) Publication bias from the evaluation about high appearance of miR-21 and Operating-system; (C) Sensitivity evaluation of the analysis about high appearance of miR-21 and Operating-system; and (D) Forest story from the analyses about low appearance of miR-34a and Operating-system or Operating-system (multivariate evaluation). No significant association between high appearance of miR-21 and RFS/CSS Three studies [6, 14, 17] centered on cable connections between high appearance of miR-21 and RFS/CSS, recommending that there is no significant association between high appearance of miR-21 and RFS/CSS (HR=2.10, 95%CI=0.72-6.12, P=0.17, Body ?Body2A2A). Publication bias To be able to SKI-606 pontent inhibitor assess publication bias for Operating-system of GC sufferers with high miR-21 appearance, the Begg’s funnel story was utilized by us (Body ?(Figure2B).2B). As well as the P worth was 0.62, indicating lack of publication bias. Awareness evaluation Through the SKI-606 pontent inhibitor research about Operating-system of GC sufferers with high miR-21 appearance, our sensitivity analysis did not indicate alterations in the results according to the exclusion of any individual study (Physique ?(Physique2C),2C), suggesting that no single research significantly influenced the pooled HR and the 95%CI. No significant association between low expression of miR-34a and OS or OS (multivariate analysis) There was no significant association between.